健信超导上市募7.8亿首日涨213% 3年经营现金流2年负

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (stock code: 688805.SH) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 58.12 yuan, reflecting a 212.81% increase from the opening price [1] Company Overview - Jianxin Superconducting focuses on the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI equipment [1] - The controlling shareholders are Xu Jianyi, Xu Hui, and Xu Dianbo, who collectively control 59.92% of the voting rights prior to the issuance [1] Shareholding Structure Post-Issue - After the issuance, the controlling shareholders still include Xu Jianyi, Xu Hui, and Xu Dianbo, with their respective holdings reduced to 31.13%, 3.27%, and 3.27% [2] - The total voting rights controlled by these shareholders decreased to 44.94% post-issue [2] Financial Performance - Revenue for Jianxin Superconducting from 2022 to 2024 was 358.93 million yuan, 450.64 million yuan, and 425.50 million yuan, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [6] - For the first nine months of 2025, the company reported revenue of 393.30 million yuan, a year-on-year increase of 37.34%, and a net profit of 47.62 million yuan, up 38.54% [10] Future Projections - The company expects to achieve revenue between 580 million yuan and 620 million yuan in 2025, representing a growth of 36.31% to 45.71% compared to 2024 [12] - Projected net profit for 2025 is estimated to be between 72 million yuan and 77 million yuan, indicating a growth of 29.07% to 38.03% [12] Fundraising and Investment Plans - Jianxin Superconducting raised a total of 778.87 million yuan from the issuance, with a net amount of 688.64 million yuan after deducting issuance costs [3] - The funds will be allocated to projects including the annual production of 600 sets of helium-free superconducting magnets and the technological transformation of high-field medical superconducting magnets [5]